Get the Stockscreener App
26.97
2.67%
-0.74
After Hours:
26.97
Alkermes Plc stock is traded at $26.97, with a volume of 2.48M.
It is down -2.67% in the last 24 hours and down -1.68% over the past month.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
See More
Previous Close:
$27.71
Open:
$27.44
24h Volume:
2.48M
Relative Volume:
1.30
Market Cap:
$4.45B
Revenue:
$1.51B
Net Income/Loss:
$333.35M
P/E Ratio:
13.83
EPS:
1.95
Net Cash Flow:
$315.22M
1W Performance:
-9.92%
1M Performance:
-1.68%
6M Performance:
-19.28%
1Y Performance:
+1.54%
1-Day Range:
$26.93
$27.68
1-Week Range:
$25.16
$28.65
52-Week Range:
$25.16
$36.45
Alkermes Plc Stock (ALKS) Company Profile
Name
Alkermes Plc
Sector
Phone
00-353-1-772-8000
Address
CONNAUGHT HOUSE, DUBLIN 4
Compare ALKS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
26.97 | 4.45B | 1.51B | 333.35M | 315.22M | 1.95 |
|
ZTS
Zoetis Inc
|
148.20 | 66.22B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.10 | 48.29B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.81 | 43.99B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
19.93 | 22.45B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
405.02 | 17.93B | 2.99B | 1.21B | 1.13B | 25.06 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-03-25 | Initiated | Wells Fargo | Overweight |
| Jul-15-25 | Initiated | Goldman | Buy |
| Jun-17-25 | Upgrade | UBS | Neutral → Buy |
| May-28-25 | Initiated | Needham | Buy |
| Mar-13-25 | Initiated | RBC Capital Mkts | Sector Perform |
| Mar-04-25 | Upgrade | UBS | Sell → Neutral |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Nov-05-24 | Upgrade | Stifel | Hold → Buy |
| Jun-17-24 | Initiated | TD Cowen | Buy |
| Mar-19-24 | Initiated | Robert W. Baird | Outperform |
| Feb-20-24 | Downgrade | UBS | Neutral → Sell |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Oct-24-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-17-23 | Initiated | UBS | Neutral |
| Nov-03-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-14-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-16-22 | Initiated | Piper Sandler | Neutral |
| Apr-22-22 | Resumed | Goldman | Buy |
| Apr-20-22 | Initiated | Goldman | Buy |
| Jan-27-22 | Upgrade | Cantor Fitzgerald | Hold → Overweight |
| Dec-01-21 | Initiated | Citigroup | Neutral |
| Oct-07-21 | Upgrade | Jefferies | Hold → Buy |
| Sep-02-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Oct-15-20 | Upgrade | Mizuho | Neutral → Buy |
| Jul-30-20 | Downgrade | Goldman | Neutral → Sell |
| Feb-14-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Feb-14-20 | Reiterated | H.C. Wainwright | Neutral |
| Feb-14-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Jan-31-20 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Sep-05-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jul-15-19 | Upgrade | Goldman | Sell → Neutral |
| May-31-19 | Initiated | H.C. Wainwright | Neutral |
| May-01-19 | Downgrade | Citigroup | Buy → Neutral |
| Dec-19-18 | Downgrade | Goldman | Neutral → Sell |
| Dec-14-18 | Initiated | Wolfe Research | Underperform |
| Dec-13-18 | Downgrade | Credit Suisse | Outperform → Underperform |
| Nov-05-18 | Initiated | Piper Jaffray | Neutral |
| Aug-07-18 | Initiated | Stifel | Hold |
| Jun-21-18 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jun-06-18 | Initiated | B. Riley FBR, Inc. | Buy |
| May-16-18 | Upgrade | Citigroup | Neutral → Buy |
| May-11-18 | Initiated | BofA/Merrill | Buy |
View All
Alkermes Plc Stock (ALKS) Latest News
Alkermes appoints Joshua Reed as new CFO effective Monday By Investing.com - Investing.com Australia
Investors Purchase Large Volume of Alkermes Call Options (NASDAQ:ALKS) - MarketBeat
Alkermes says on Sept 9, unit granted Amneal rights to sell generic version of VivitrolSEC filing - MarketScreener
Alkermes Appoints Joshua Reed as New CFO - TipRanks
Alkermes plc Appoints Joshua Reed as Chief Financial Officer, Effective Date Is September 15, 2025 - MarketScreener
Alkermes appoints Joshua Reed as new CFO effective Monday - Investing.com
Alkermes (ALKS) Appoints Joshua Reed as New CFO - GuruFocus
30-Year Biotech Finance Veteran Joshua Reed Joins Alkermes as CFO After Bristol Myers Leadership - Stock Titan
While Shareholders of Alkermes (NASDAQ:ALKS) Are in the Black Over 5 Years, Those Who Bought a Week Ago Aren't so Fortunate - 富途牛牛
Alkermes Announces Launch of 8th Annual Alkermes Pathways Research Awards® Program - Eastern Progress
Fred Alger Management LLC Takes $1.24 Million Position in Alkermes plc $ALKS - MarketBeat
AQR Capital Management LLC Sells 279,276 Shares of Alkermes plc $ALKS - MarketBeat
Alkermes (NASDAQ:ALKS) Price Target Raised to $35.00 - MarketBeat
Alkermes' (ALKS) Neutral Rating Reaffirmed at HC Wainwright - MarketBeat
Potential Impact on Alkermes (ALKS) from RFK Jr.'s Possible Depa - GuruFocus
How RFK Jr.'s Potential Exit Could Benefit Alkermes (ALKS) - GuruFocus
Alkermes (NASDAQ:ALKS) Hits New 52-Week LowTime to Sell? - MarketBeat
December 2026 Options Now Available For Alkermes (ALKS) - Nasdaq
Can Alkermes plc stock outperform in a bear market2025 Risk Factors & Stepwise Trade Signal Guides - Lancaster City Council
HC Wainwright & Co. Reiterates Neutral Rating for ALKS | ALKS St - GuruFocus
Alkermes Announces Positive Phase 2 Study Results - MSN
Alkermes (NASDAQ:ALKS) Stock Rating Upgraded by Wells Fargo & Company - MarketBeat
Alkermes plc $ALKS Shares Acquired by Canada Pension Plan Investment Board - MarketBeat
Is Alkermes plc stock showing strong momentumJuly 2025 Spike Watch & Reliable Breakout Forecasts - 뉴스영
Alkermes stock hits 52-week low at 25.31 USD By Investing.com - Investing.com Canada
Alkermes (ALKS) Reports Promising Results from Phase 2 Narcoleps - GuruFocus
Alkermes reports positive phase 2 results for narcolepsy drug By Investing.com - Investing.com Canada
Takeda and Alkermes share OX2R drug data for narcolepsy - Yahoo Finance
Alkermes stock hits 52-week low at 25.31 USD - Investing.com
Alkermes (ALKS) Shows Progress in Narcolepsy Study, Faces Invest - GuruFocus
Alkermes : ALKS World Sleep 2025 Prepared Remarks 9 8 2025 FINAL - MarketScreener
Transcript : Alkermes plcShareholder/Analyst Call - MarketScreener
Alkermes stock maintains Buy rating at Stifel following sleep disorder data - Investing.com Nigeria
Real Time Data Flags Unusual Activity in Alkermes plc2025 Investor Takeaways & Daily Oversold Bounce Ideas - beatles.ru
Alkermes plc $ALKS Position Trimmed by Palo Alto Investors LP - MarketBeat
Alkermes (ALKS) Reports Promising Phase 2 Results for Narcolepsy Treatment Alixorexton - GuruFocus
Alkermes reports positive phase 2 results for narcolepsy drug - Investing.com
Alkermes Investigational Narcolepsy Drug Meets Primary, Secondary Endpoints in Phase 2 Study - MarketScreener
Alkermes presents detailed positive results from Vibrance-1 Phase 2 Study of Alixorextin in patients with narcolepsy type 1 - MarketScreener
Alkermes Presents Detailed Positive Results from Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at World Sleep Congress 2025 - Yahoo Finance
Alkermes (NASDAQ:ALKS) Trading 7.2% Higher Following Analyst Upgrade - MarketBeat
337,603 Shares in Alkermes plc $ALKS Acquired by MPM Bioimpact LLC - MarketBeat
Alkermes plc $ALKS Shares Purchased by Baker BROS. Advisors LP - MarketBeat
Does Alkermes plc show high probability of reboundWeekly Trade Recap & Consistent Income Trade Recommendations - Newser
When is the best time to exit Alkermes plcWeekly Risk Summary & Daily Oversold Bounce Ideas - Newser
Can swing trading help recover from Alkermes plc lossesRate Cut & AI Enhanced Trading Signals - Newser
PDT Partners LLC Increases Stock Position in Alkermes plc $ALKS - MarketBeat
Visual analytics tools that track Alkermes plc performanceProfit Target & Free Growth Oriented Trading Recommendations - Newser
Can Alkermes plc maintain sales growthJuly 2025 Short Interest & Weekly High Return Stock Opportunities - خودرو بانک
Is Alkermes plc in a long term uptrendJuly 2025 News Drivers & Stepwise Trade Execution Plans - خودرو بانک
How to use a screener to detect Alkermes plc breakoutsRecession Risk & Low Drawdown Investment Ideas - Newser
Alkermes Plc Stock (ALKS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.33%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):